Hepatitis B Treatment Market Sales Revenue, Emerging Technologies and Growth Analysis

19/mar/2020 10:55:47 Market Research Future Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

 Key Players:

  • Accord Healthcare Inc
  • Apotex Corp
  • Arbutus Biopharma
  • Arrowhead Pharma
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • Merck & Co

Market Highlights:

The global Hepatitis B Treatment Market is expected to grow at an approximate CAGR of 5.3% during the forecast period, 2018–2024.
Hepatitis B is a viral infection caused by a hepatitis B virus. This infection lasts for a longer period and can cause many other complications, such as scarring in the liver, liver cancer or liver failure. The person suffering from hepatitis B faces various symptoms such as fever, fatigue, nausea, and muscle aches. The other symptoms include jaundice, swelling in the legs, poor appetite, drowsiness and many more. The key factors contributing the market growth are growing geriatric population, increasing the prevalence of viral infection and growing sexually transmitted diseases among the population contribute to driving the market growth. The World Hepatitis Alliance (WHA), 2017 reported that 52 million children across the world are living with viral hepatitis. Such a huge population suffering from Hepatitis boosts the market growth.


However, the factor such as the side effects or complication caused due to treatment may hamper the market growth. 

Segmentation:

  • The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
  • Based on type, the market is segmented into acute and chronic.
  • On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others.
  • By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.

Regional Analysis:

The Americas dominates the global market for hepatitis B treatment. Factors such as the presence of a large number of healthcare companies, increasing geriatric population and high healthcare expenditure among the population within the Americas drives the market. The National Vaccine Information Center reported 3,370 cases of hepatitis B were reported in the US in 2015.

Following similar trends, Europe stood second in the global hepatitis B treatment market. The increased prevalence of viral diseases and growing healthcare expenditure in this region boost market growth. Also, the presence of developed economies, increasing healthcare facilities, and rising government funding for healthcare boost market growth. Asia Pacific was the fastest growing region for the global hepatitis B treatment market in 2017. This can be attributed due to the increasing incidences of HIV infection and rising demand for the treatment of viral infection among the population boosts market growth. 

Related News

Clinical Laboratory Services Market share

Sterilization Equipment Market trends

About Market Research Future:

MRFR team has supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country-level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl